Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: Ultimovacs Begins Clinical Evaluation of Novel TET-Platform

After presenting their 2020 Q4 report, Ultimovacs immediately turned their attention back to 2021 by announcing the initiation of a new phase I study, TENDU. The TENDU trial is aimed at testing the company’s TET-platform in prostate cancer patients. The platform is based on innovative patented technology that has the potential to generate multiple cancer vaccine candidates.Read the full article at biostock.se: https://www.biostock.se/2021/02/ultimovacs-paborjar-klinisk-evaluering-av-ny-tet-platform/   This is a press release from BioStock - Connecting Innovation & Capital.

Nordic Mining ASA: New share capital registered

Reference is made to the stock exchange release from Nordic Mining ASA ("Nordic Mining" or the "Company") published 24 February 2021 regarding the completion of the Private Placement. The Private Placement consisted of 32,000,000 new shares at a subscription price of NOK 2.50 per share, each with a par value of NOK 0.60. The share capital increase has been registered with the Norwegian Register of Business Enterprises today. Following registration of the new share capital Nordic Mining’s share capital has increased by NOK 19,200,000 to NOK 137,695,063.20 divided into 229,491,772

Contract awards in Australia

Solstad Offshore ASA (“Solstad”) is pleased to confirm that the large AHTS Normand Ranger has been awarded a contract in Australia for commencement in 2Q 2021. The vessel will mobilise from Norway and will then provide support to a major drilling campaign offshore North Western Australia, securing about 1 year of utilization for the vessel. During the drilling campaign, that also includes support from the Solstad AHTSs Normand Saracen and Far Senator, the Normand Ranger will operate in connection with a moored semi-submersible drilling rig, with the base port being Dampier. In

Salmon Evolution executes on Asia growth strategy – establishes joint venture with seafood giant Dongwon Industries

Molde/Ålesund/Seoul, 26 February 2021: Salmon Evolution Holding AS (“Salmon Evolution” or the “Company”, OSE: SALME) – a leading land-based salmon farming business with its first production facility under construction at Indre Harøy in western Norway – is pleased to inform that the company today has signed a Joint Venture Term Sheet with Dongwon Industries, a leading seafood company based in South Korea, for the establishment of a 49/51 joint venture, to be named K Smart Farming (“K Smart”).  Key highlights: · 20,000 tons LWE production facility in South Korea using Salmon Evolution’

Invitation to Asetek's Capital Markets Update on Thursday 4 March

February 26, 2021 - Asetek is pleased to invite investors, analysts, media and other stakeholders to its Capital Markets Update (CMU) and Q4 2020 earnings presentation on Thursday 4 March 2021. The CMU presentation will be given in English by CEO André Sloth Eriksen, COO John Hamill, CFO Peter Dam Madsen and VP & General Manager Jim Carlton, and will be published as a webcast with accompanying slides. The CMU will provide an update on Asetek’s strategy, markets, operations, financial development and outlook. Asetek’s recent investments in IP, software and hardware as part of

Q2 - Interim Report October 2020 – December 2020

Opening remarks The second quarter of this fiscal year has been very productive for Hamlet Pharma. The clinical trials program has continued and in January, the first patient was included.  The patients will receive increased doses of Alpha1H or combination therapy with Alpha1H and low doses of Epirubicin, an established bladder cancer drug. Information from this study program will be essential for the design of Phase III trials. Despite the COVID-19 pandemic, the team in Prague is very motivated and drives the clinical activities forward to develop Alpha1H towards a new drug for patients

Interim Financial Report

January – December 2020 Despite the significant challenges related to Covid-19, including a revenue drop of nearly 45% experienced in Q2, our second half revenue rebounded to pre pandemic levels. Solid recovery in Commercial Vehicle markets and maturation of key Passenger Car programs spearheaded the improvement. Q4 revenue coming in at 463.3 MSEK was particularly encouraging. 2020 Full year performance improved by 160 basis points in adjusted EBITDA margin coming in at 8.2% versus 6.8% adjusted EBITDA margin in 2019. This improvement comes despite Q2 2020 margin at (-0.4%) versus 6.7%

YEAR END REPORT Period from January 2020 to December 2020

Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03 Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED) Group, Lune Group OY incl subsidiary is included from 2020-06-03 2020 FOURTH QUARTER (Oct-Dec) · Net sales of products KSEK 7,258 (394) · Gross profit KSEK 3,866 (321), Gross margin 53% (81%) · Operating loss KSEK -10,702 (-11,508)  · Loss per share SEK -0.07 (-0.08) FULL YEAR 2020 (Jan-Dec) · Net sales of products KSEK 21,283 (4,408) · Gross profit KSEK 13,089 (2,583), Gross margin 61% (59%) ·

MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2020

Promising clinical results, successful business development and secured financingOctober – DecemberFinancial summary for the quarter · Net turnover amounted to SEK 1.5 (1.4) million. · The profit before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -10.6(-30.3) million. Basic and diluted earnings per share amounted to SEK -0.46 (-1.32) and SEK -0.46 (-1.32) respectively. · Cash flow from operating activities amounted to SEK -1.0 (-23.6) million. · Liquid assets and short-term investments at the end of the period amounted to SEK 70.0 (134.5) million.

Interim Financial Report – full year of 2020 (incl. Q4 2020)

Q4 of 2020 consolidated financial statements describe the operating results of SGL TransGroup International A/S (SGL Group). · The Q4 2020 revenue was DKK 1,492 million, the full year of 2020 revenue was DKK 5,351 million and increased by 29% vs the full year of 2019. · The Q4 2020 Gross Profit was DKK 249 million, the full year of 2020 Gross Profit was DKK 955 million and the Gross Margin equals 17.8%. · The Q4 2020 EBITDA before special items excl. IFRS 16 amounts to DKK 53 million, the full year of 2020 EBITDA before special items excl. IFRS 16 was DKK 237 million; equal to an

Invitation to the webcast on Fortum's Financial Statements Bulletin 2020

FORTUM CORPORATION INVESTOR NEWS 26 FEBRUARY 2021 AT 9:30 EET Fortum's Financial Statements Bulletin 2020 will be published on 12 March 2021 at approximately 9:00 EET. A combined live webcast/teleconference for media, investors, and analysts will be arranged online on the same day at 11:00 EET. For the webcast, use the link on www.fortum.com/investors. To participate in the teleconference and Q&A, dial in using the numbers below: FI: +358 9 817 10310UK: +44 333 300 0804US: +1 631 913 1422 PIN: 43874018# A recording of the webcast as well as the transcript will be

Year-End Report Nanologica 2020

SUMMARY OF THE PERIODFINANCIAL OVERVIEW · Net revenue increased by 75 percent to TSEK 16 135 (9 227) in total, of which the fourth quarter TSEK 6 071 (2 731) · The operating result for the period was TSEK -19 571 (-20 066), of which the fourth quarter TSEK -3 648 (-6 260) · Loss for the period was TSEK -22 199 (-21 080), of which the fourth quarter TSEK -5 427 (-6 855) · Loss per share for the period was SEK -0,93 (-1,27), of which the fourth quarter SEK -0,20 (-0,41) · Cash and cash equivalents at the end of the period amounted to TSEK  66 364 (1 176) SIGNIFICANT EVENTS

Article from Phase II study in prostate cancer now published in the March issue of Journal of Nuclear Medicine and highlighted as best clinical investigation article

As previously communicated in December 2020, results from the investigator-initiated phase II study performed by researchers at Rigshospitalet were available in 2020. Now, these results are published in the March 2021 issue of the Journal of Nuclear Medicine, which is the most recognized scientific journal in the field of nuclear medicine (highest impact factor). Furthermore, the article (available here)  has been selected as Featured Clinical Investigation Article of the March issue.The phase II study The phase II study aimed to evaluate the

Change in Number of Shares in Nanologica AB

The number of shares in Nanologica AB (publ) has changed during the month of February as a result of options from the stock option program 2018/21 being exercised.A share-based incentive program of a maximum of 483 883 options was decided by the Annual General Meeting May 31, 2018. The program expires July 1st, 2021 and the options may be exercised any time before that to a strike price of SEK 9.3. According to the Financial Instruments Trading Act (1991:980), any changes in the total number of shares in Swedish publicly traded companies shall be made public per the last day of trade of the

Kamux’s transfer of own shares for payment of share-based incentives 2020

Kamux Corporation    Stock Exchange Release    26 February 2021 at 9:10 (EET) Kamux’s transfer of own shares for payment of share-based incentives 2020 The Board of Directors of Kamux Corporation (“Company”) has confirmed the remuneration to be paid to the key personnel of the Kamux Group in accordance with the terms and conditions of the share-based incentive scheme and the earnings criteria set for the year 2020. According to the terms and conditions of the share-based incentive scheme 2020 and after the deduction of the cash payment portions of the remunerations meant for taxes and

Changes in the roles and responsibilities of the members of Kamux Corporation’s Management Team

Kamux Corporation    Stock Exchange Release    26 February 2021 at 9:10 (EET) Changes in the roles and responsibilities of the members of Kamux Corporation’s Management Team Tommi Iiskonmäki (b. 1977, M.Sc. Econ.) has been appointed as Country Director of Kamux Sweden and he will continue in his new position as Member of the Group Management Team. Earlier he has acted as Country Director of Kamux Finland and Member of the Group Management Team, in addition also as HR Director, and in 2016―2017 as acting Country Director of Kamux Sweden. Ilkka Virtanen (b. 1980, M.Sc. Econ.) has

Axactor SE - Acceptances received under mandatory offer

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Reference is made to the mandatory offer dated 29 January 2021 (the "Mandatory Offer") to acquire all shares in Axactor SE (the "Company") at an offer price of NOK 8.00 per share, made by Geveran Trading Co. Limited, a company indirectly controlled by trusts established by Mr. John Fredriksen for the benefit of his immediate family ("Geveran").  On 25 February 2021,

Otello Announces Definitive Agreement to sell AdColony to Digital Turbine

Otello announced today that it has entered into a definitive agreement to sell AdColony to Digital Turbine, Inc. (Nasdaq: APPS) for a total estimated consideration of $400 million. Digital Turbine is a global mobile technology company, passionate about delivering the right content to the right person at the right time across all Android devices. The company’s on-demand media platform powers frictionless app and content discovery, user acquisition and engagement, operational efficiency, and monetization opportunities. Digital Turbine’s technology platform has been adopted by more than 40

Alligator Bioscience AB: Year-end Report January-December 2020

Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with metastatic cancer. The results show a promising safety profile with only minor drug-related side effects.”  Per Norlén, CEO Alligator Bioscience   SIGNIFICANT EVENTS OCTOBER-DECEMBERMitazalimab:•    New preclinical comparative data showed that mitazalimab has highly competitive immunostimulatory characteristics.•    IND approved for forthcoming clinical studies in the US.•    CTA submitted for launch of the forthcoming Phase II study in

Conversion of shares

According to Essity’s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company. When such a conversion has occurred, the company is obligated by law to disclose any such changes in this manner.In February, at the request of shareholders, 600 Class A shares were converted to Class B shares. The total number of votes in the company thereafter amounts to 1,257,952,737. The total number of registered shares in the company amounts to 702,342,489 of which 61,734,472 are Class A

Change in the number of shares and votes in BioInvent International AB

Lund, Sweden, February 26, 2021 – BioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the company’s total number of shares as per February 26, 2021 amounts to 42,210,495 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the directed issue of MSEK 143 to Swedish and international institutional investors by issuance of 2,834,399 shares, announced on February 23, 2021.   About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical stage company that discovers and develops novel

Bluestep Bank AB (publ) Year-End Report 2020

The year in brief   Performance and financial position · Lending to the public amounted to SEK 16 116m (SEK 16 150m). Growth was reduced by both the sale of the personal loan portfolio and weakening of the Norwegian krone (NOK). Adjusted for personal loans and currency effects, lending rose by 12%. · New lending for the year increased by 7% to SEK 6 197m (SEK 5 805m). Adjusted for personal loans and currency effects, the increase was 22%. · Full year operating profit amounted to SEK 215m (SEK 275m). The decrease is attributable to one-off costs resulting from restructuring

Electrolux Professional acts for food support and sustainable cooking together with the Electrolux Food Foundation

Electrolux Professional is proud to announce the support of the Electrolux Food Foundation, an independent, non-profit organization that supports initiatives to inspire more sustainable food choices among professionals and consumers, and to support people in need in the communities around us.Since food is a major battleground in the fight against climate change, the foundation’s focus is well aligned with the Electrolux Professional commitment to contribute to change through its Sustainability Commitment, that supports the UN Agenda 2030 and Sustainable Development Goals. Niklas

Year-end report: First commercial installation of TES.POD started in Dubai

Azelio won its first order for TES.POD® in December. The company thus reached a major milestone in the commercialisation of its energy storage system. The order is from ALEC Energy, which will install Azelio’s technology in one of the world’s largest solar parks, the Mohammed Bin Rashid Al Maktoum Solar Complex in Dubai, where it will be part of a mini-grid together with inter alia solar panels and batteries. This will provide renewable energy 24 hours a day, which is an important step in meeting the climate transition. Azelio began installation on site on 20 December. In the fourth

There are no items matching the current filter
There are no more items matching the current filter
Back to top